Aspire Biopharma closes second tranche of $21M preferred offering; funds Dura Driver acquisition

Aspire Biopharma Holdings, Inc.

Closed second tranche of Series A Convertible Preferred stock on April 15, 2026 for 12,500 shares and gross proceeds of ~$10M.
Combined with first tranche (13,750 shares, $11M), total offering raises $21M before fees.
Amended Certificate of Designation to increase authorized Series A shares from 25,000 to 30,000.
Net proceeds to fund cash portion of proposed Dura Driver Control Systems acquisition and for general corporate purposes.
RBW Capital Partners acting through Dawson James Securities acted as placement agent.

item 1.01item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.